Literature DB >> 24936226

Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review.

Louis de Mestier1, Gilles Manceau1, Cindy Neuzillet1, Jean Baptiste Bachet1, Jean Philippe Spano1, Reza Kianmanesh1, Jean Christophe Vaillant1, Olivier Bouché1, Laurent Hannoun1, Mehdi Karoui1.   

Abstract

At the time of diagnosis, 25% of patients with colorectal cancer (CRC) present with synchronous metastases, which are unresectable in the majority of patients. Whether primary tumor resection (PTR) followed by chemotherapy or immediate chemotherapy without PTR is the best therapeutic option in patients with asymptomatic CRC and unresectable metastases is a major issue, although unanswered to date. The aim of this study was to review all published data on whether PTR should be performed in patients with CRC and unresectable synchronous metastases. All aspects of the management of CRC were taken into account, especially prognostic factors in patients with CRC and unresectable metastases. The impact of PTR on survival and quality of life were reviewed, in addition to the characteristics of patients that could benefit from PTR and the possible underlying mechanisms. The risks of both approaches are reported. As no randomized study has been performed to date, we finally discussed how a therapeutic strategy's trial should be designed to provide answer to this issue.

Entities:  

Keywords:  Chemotherapy; Colorectal cancer; Colorectal primary tumor; Colorectal surgery; Liver metastases; Survival

Year:  2014        PMID: 24936226      PMCID: PMC4058723          DOI: 10.4251/wjgo.v6.i6.156

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  93 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  How aggressive should we be in patients with stage IV colorectal cancer?

Authors:  Li-Jen Kuo; Shuh-Yan Leu; Mei-Ching Liu; James Jer-Min Jian; Skye Hongiun Cheng; Chung-Ming Chen
Journal:  Dis Colon Rectum       Date:  2003-12       Impact factor: 4.585

3.  Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACHBT). Short version.

Authors:  S Zalinski; C Mariette; O Farges
Journal:  J Visc Surg       Date:  2011-06-24       Impact factor: 2.043

4.  Initial presentation with stage IV colorectal cancer: how aggressive should we be?

Authors:  S A Rosen; J F Buell; A Yoshida; S Kazsuba; R Hurst; F Michelassi; J M Millis; M C Posner
Journal:  Arch Surg       Date:  2000-05

5.  Use of surgery among elderly patients with stage IV colorectal cancer.

Authors:  Larissa K F Temple; Lillian Hsieh; W Douglas Wong; Leonard Saltz; Deborah Schrag
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

6.  Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601.

Authors:  F Ferrand; D Malka; A Bourredjem; C Allonier; O Bouché; S Louafi; V Boige; M Mousseau; J L Raoul; L Bedenne; B Leduc; P Deguiral; M Faron; J P Pignon; M Ducreux
Journal:  Eur J Cancer       Date:  2012-08-25       Impact factor: 9.162

7.  Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.

Authors:  M Ychou; F Viret; A Kramar; F Desseigne; E Mitry; R Guimbaud; J R Delpero; M Rivoire; F Quénet; G Portier; B Nordlinger
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-28       Impact factor: 3.333

8.  The role of primary tumour resection in patients with stage IV colorectal cancer.

Authors:  V R Konyalian; D K Rosing; J S Haukoos; M R Dixon; R Sinow; S Bhaheetharan; M J Stamos; R R Kumar
Journal:  Colorectal Dis       Date:  2007-06       Impact factor: 3.788

9.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

10.  Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature.

Authors:  Sabine Venderbosch; Johannes H de Wilt; Steven Teerenstra; Olaf J Loosveld; Aart van Bochove; Harm A Sinnige; Geert-Jan M Creemers; Margot E Tesselaar; Linda Mol; Cornelis J A Punt; Miriam Koopman
Journal:  Ann Surg Oncol       Date:  2011-08-06       Impact factor: 5.344

View more
  11 in total

1.  Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis.

Authors:  Jiefeng Zhao; Jinfeng Zhu; Rui Sun; Chao Huang; Rongfa Yuan; Zhengming Zhu
Journal:  BMC Cancer       Date:  2021-05-06       Impact factor: 4.430

2.  A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.

Authors:  Takahiro Horimatsu; Norisuke Nakayama; Toshikazu Moriwaki; Yoshinori Hirashima; Mikio Fujita; Masako Asayama; Ichiro Moriyama; Koji Nakashima; Eishi Baba; Hiroshi Kitamura; Takao Tamura; Ayumu Hosokawa; Kenichi Yoshimura; Manabu Muto
Journal:  Int J Clin Oncol       Date:  2017-05-23       Impact factor: 3.402

3.  The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis.

Authors:  Fangfang Sun; Weiwei Liang; Jing Qian
Journal:  Mol Med Rep       Date:  2019-08-14       Impact factor: 2.952

4.  Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status.

Authors:  Fotios Loupakis; Giulia Maddalena; Ilaria Depetris; Sabina Murgioni; Francesca Bergamo; Angelo Paolo Dei Tos; Massimo Rugge; Giada Munari; Andrew Nguyen; Christopher Szeto; Vittorina Zagonel; Sara Lonardi; Matteo Fassan
Journal:  J Immunother Cancer       Date:  2019-11-08       Impact factor: 13.751

5.  Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer.

Authors:  Wenlong Du; Xiaoping Yang; Shenfu He; Jia Wang; Yuanxian Guo; Bangguo Kou; Yongjie Jiang; Pan Bian; Bingtai Li; Lanning Yin
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

6.  Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre).

Authors:  Ruba A Hamed; Sam Marks; Helen Mcelligott; Roshni Kalachand; Hawa Ibrahim; Said Atyani; Greg Korpanty; Nemer Osman
Journal:  Mol Clin Oncol       Date:  2021-12-21

7.  Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy.

Authors:  Maha S Al-Keilani; Dua H Alsmadi; Ruba S Darweesh; Karem H Alzoubi
Journal:  Clin Pharmacol       Date:  2018-03-05

8.  Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?

Authors:  Yakup Ergun; Oznur Bal; Mutlu Dogan; Gokhan Ucar; Merve Dirikoc; Yusuf Acikgoz; Ferhat Bacaksiz; Dogan Uncu
Journal:  J Res Med Sci       Date:  2020-02-20       Impact factor: 1.852

9.  Clinicopathological spectrum of colorectal cancer among the population of the KwaZulu-Natal Province in South Africa.

Authors:  Thandinkosi Madiba; Yoshan Moodley; Benn Sartorius; Kurt Sartorius; Colleen Aldous; Maseelan Naidoo; Vishendran Govindasamy; Shona Bhadree; Laura Stopforth; Yuming Ning; Pokala Ravi Kiran
Journal:  Pan Afr Med J       Date:  2020-09-18

10.  Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes.

Authors:  Nicolas Voizard; Tiffany Ni; Alex Kiss; Robyn Pugash; Michael Jonathon Raphael; Natalie Coburn; Elizabeth David
Journal:  Curr Oncol       Date:  2022-01-06       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.